These results confirm our previous observation that H4R ligands could have beneficial effects in decreasing lung fibrosis in WT (Lucarini et al., 2016) and in PARP-1−/− animals, indicating that the treatment with H4R antagonists exerts its beneficial effects also in situation of PARP-1 deletion. This evidence concerns the gene PARP1 and pulmonary fibrosis.